[Clinical trials demonstrated that JAK1/2 inhibitors ameliorate constitutional symptoms and reduce spleen size in patients with myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
Gene-disease associations inferred from text-mining the literature.
DisGeNET evidence - LITERATURE